Chiba W, Sawai S, Ikeda S, Morimoto K, Wazawa H, Hanawa T, Yamashita N, Matsui T, Hatakenaka R, Matsubara Y
Respiratory Disease Center, Kyoto-Katsura Hospital.
Gan To Kagaku Ryoho. 1994 May;21 Suppl 1:108-16.
We quantitatively analyzed the c-myc and p53 products using flow cytometry in 28 cases of resected lung cancer and one case each of chorio-carcinoma, plasmacytoma, malignant mesothelioma and sclerosing hemangioma. In the lung cancer cases, c-myc and p53 products were detected in 10 cases (35%) and 7 cases (21%), respectively. These rates are higher than the DNA abnormal expression rates of the c-myc and p53 genes (15% and 12%, respectively) in our own data. In the adenocarcinoma of lung cancer cases, c-myc and p53 products were detected in 9 cases (53%) and 5 cases (29%), respectively. Among the squamous cell carcinoma cases, there were one case (11%) of c-myc expression and one case (11%) of p53 expression. DNA content analysis of the lung cancer patients revealed 7 cases of DNA diploidy and 21 cases of DNA aneuploidy. All 10 c-myc-positive cases showed DNA aneuploidy; thus the positive rate for c-myc products in the DNA aneuploidy cases was significantly different compared with the DNA diploidy cases (p < 0.05). In the sclerosing hemangioma case, we detected both c-myc and p53 products. Sclerosing hemangioma has been thought to be a benign tumor, but it may be a malignant tumor.
我们采用流式细胞术对28例切除的肺癌以及1例绒毛膜癌、1例浆细胞瘤、1例恶性间皮瘤和1例硬化性血管瘤进行了c-myc和p53产物的定量分析。在肺癌病例中，分别有10例（35%）检测到c-myc产物，7例（21%）检测到p53产物。这些比率高于我们自身数据中c-myc和p53基因的DNA异常表达率（分别为15%和12%）。在肺癌腺癌病例中，分别有9例（53%）检测到c-myc产物，5例（29%）检测到p53产物。在鳞状细胞癌病例中，有1例（11%）c-myc表达，1例（11%）p53表达。肺癌患者的DNA含量分析显示，7例为DNA二倍体，21例为DNA非整倍体。所有10例c-myc阳性病例均显示为DNA非整倍体；因此，DNA非整倍体病例中c-myc产物的阳性率与DNA二倍体病例相比有显著差异（p<0.05）。在硬化性血管瘤病例中，我们检测到了c-myc和p53产物。硬化性血管瘤一直被认为是一种良性肿瘤，但它可能是恶性肿瘤。
